People · Operator
Named in public records as an officer, director or promoter · active 2014–2021 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lucy Therapeutics, Inc. | — | Pharmaceuticals | Series B | $28.6M | $91.6M | 2021 |
| Alkahest, Inc. | — | Biotechnology | Seed | $3.5M | $155.4M | 2014 |
| Biommune Technologies Inc. | — | Biotechnology | Pre-Seed | $600K | $33.1M | 2015 |
Karoly Nikolich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karoly Nikolich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann DeWitt | 1 | 10 |
| John Ripple | 1 | 4 |
| Rachel Sha | 1 | 4 |
| TERRY PEARSON | 1 | 2 |
| Michael Hutchison | 1 | 2 |
| Reinhard Gabathuler | 1 | 1 |
| JENS BIERTUMPEL | 1 | 1 |
| Judi Dalling | 1 | 1 |
| Anton Wyss-Coray | 1 | 1 |
| Rob Hutchison | 1 | 1 |
| Tamara Kent | 1 | 1 |
| Robert Michael Poole | 1 | 1 |
| Amy Ripka | 1 | 1 |
| PATRICK W. GRAY | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.